The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children
Abstract
BACKGROUND: The efficacy of inactivated influenza vaccines is known to be poor in infants and young children. METHODS: We studied the effect of the adjuvant MF59, an oil-in-water emulsion, on the efficacy of trivalent inactivated influenza vaccine (TIV) in 4707 healthy children 6 to less than 72 months of age who had not previously been vaccinated against influenza. The children were randomly assigned to three study groups, each of which received the assigned vaccines in two doses, 28 days apart, during two consecutive influenza seasons. Two of the groups were given age-appropriate doses of TIV either with or without the MF59 adjuvant, and the third group was given control (noninfluenza) vaccines to assess their absolute and relative efficacy against influenza-like illness, as confirmed by means of polymerase-chain-reaction (PCR) assay. RESULTS: Attack rates of influenza-like illness across both influenza seasons were 0.7%, 2.8%, and 4.7% in the adjuvant, nonadjuvant, and control vaccine groups, respectively. The absolute vaccine efficacy rates against all influenza strains (94 of 110 cases were due to vaccine-matched H3N2 viruses) were 86% (95% confidence interval [CI], 74 to 93) for the MF59-adjuvant vaccine (ATIV) and 43% (95% CI, 15 to 61) for the vaccine without the adjuvant (TIV); the relative vaccine efficacy rate for ATIV versus TIV was 75% (95% CI, 55 to 87). The efficacy rates for ATIV were 79% (95% CI, 55 to 90) in children 6 to less than 36 months of age and 92% (95% CI, 77 to 97) in those 36 to less than 72 months of age, as compared with 40% (95% CI, -6 to 66) and 45% (95% CI, 6 to 68), respectively, for TIV. Antibody responses were higher with ATIV and remained so through day 181. The rates of systemic and local reactions to the influenza vaccines with and without the adjuvant were similar in the younger age group (relative risk, 1.04; 95% CI, 0.98 to 1.09), but systemic events in the older age group were more frequent after administration of ATIV (63%) than after administration of TIV (44%) or the control vaccine (50%). Serious adverse events were distributed evenly across the three vaccine groups. CONCLUSIONS: Influenza vaccine with the MF59 adjuvant is efficacious against PCR-confirmed influenza in infants and young children. (Funded by Novartis Vaccines and Diagnostics; ClinicalTrials.gov number, NCT00644059.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,011
Neuzil, K. M., Mellen, B. G., Wright, P. F., Mitchel, E. F., & Griffin, M. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001273420401 · Cited by 1,096
The Underrecognized Burden of Influenza in Young Children
Poehling, K. A., Edwards, K. M., Weinberg, G. A., Szilagyi, P., Staat, M. A., Iwane, M. K., Bridges, C. B., Grijalva, C. G., Zhu, Y., Bernstein, D. I., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054869 · Cited by 872
Live Attenuated versus Inactivated Influenza Vaccine in Infants and Young Children
Belshe, R. B., Edwards, K. M., Vesikari, T., Black, S. V., Walker, R. E., Hultquist, M., Kemble, G., & Connor, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065368 · Cited by 811
Self-citationVaccines for preventing influenza in healthy children
Jefferson, T., Rivetti, A., Di Pietrantonj, C., Demicheli, V., & Ferroni, E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004879.pub4 · Cited by 553
Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine
Clark, T. W., Pareek, M., Hoschler, K., Dillon, H., Nicholson, K. G., Groth, N., & Stephenson, I. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907650 · Cited by 445
Interpandemic Influenza in the Houston Area, 1974–76
Glezen, W. P., Couch, R. B., MacLean, R. A., Payne, A., Baird, J. N., Vallbona, C., Tristan, M., & Byrd, N. (1978) · New England Journal of Medicine · doi:10.1056/nejm197803162981103 · Cited by 386
Loeb, M., Russell, M. L., Moss, L., Fonseca, K., Fox, J., Earn, D. J. D., Aoki, F., Horsman, G., Van Caeseele, P., Chokani, K., et al. (2010) · JAMA · doi:10.1001/jama.2010.250 · Cited by 384
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
Podda, A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00499-0 · Cited by 333
Modification of an Outbreak of Influenza in Tecumseh, Michigan by Vaccination of Schoolchildren
Monto, A. S., Davenport, F. M., Napier, J. A., & Francis, T. (1970) · The Journal of Infectious Diseases · doi:10.1093/infdis/122.1-2.16 · Cited by 316
Barker, W. H. (1986) · American Journal of Public Health · doi:10.2105/ajph.76.7.761 · Cited by 290
O’Hagan, D. T. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.699 · Cited by 282
Hoberman, A., Greenberg, D. P., Paradise, J. L., Rockette, H. E., Lave, J. R., Kearney, D. H., Colborn, D. K., Kurs-Lasky, M., Haralam, M. A., Byers, C. J., et al. (2003) · JAMA · doi:10.1001/jama.290.12.1608 · Cited by 280
NEUZIL, K. M., DUPONT, W. D., WRIGHT, P. F., & EDWARDS, K. M. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200108000-00004 · Cited by 227
Schultze, V., D’Agosto, V., Wack, A., Novicki, D., Zorn, J., & Hennig, R. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.03.093 · Cited by 227
Jefferson, T., Smith, S., Demicheli, V, Harnden, A., Rivetti, A., & Di Pietrantonj, C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17984-7 · Cited by 200
Banzhoff, A., Gasparini, R., Laghi-Pasini, F., Staniscia, T., Durando, P., Montomoli, E., Capecchi, P., di Giovanni, P., Sticchi, L., Gentile, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004384 · Cited by 194
Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant
Vesikari, T., Pellegrini, M., Karvonen, A., Groth, N., Borkowski, A., O'Hagan, D. T., & Podda, A. (2009) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31819d6394 · Cited by 190
Self-citationRhorer, J., Ambrose, C. S., Dickinson, S., Hamilton, H., Oleka, N. A., Malinoski, F. J., & Wittes, J. (2009) · Vaccine · doi:10.1016/j.vaccine.2008.11.093 · Cited by 189
Pellegrini, M., Nicolay, U., Lindert, K., Groth, N., & Della Cioppa, G. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.08.101 · Cited by 183
Ritzwoller, D. P., Bridges, C. B., Shetterly, S., Yamasaki, K., Kolczak, M., & France, E. K. (2005) · Pediatrics · doi:10.1542/peds.2005-0049 · Cited by 182
Sugaya, N. (1994) · JAMA · doi:10.1001/jama.1994.03520140052037 · Cited by 148
Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations
Atmar, R. L., Keitel, W., Patel, S. M., Katz, J. M., She, D., Sahly, H. M. E., Pompey, J. M., Cate, T. R., & Couch, R. B. (2006) · Clinical Infectious Diseases · doi:10.1086/508174 · Cited by 148
Belshe, R. B., Coelingh, K. L., Ambrose, C. S., Woo, J. C., & Wu, X. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.11.068 · Cited by 146
Hemagglutination inhibition assays
CROSS, G. (2002) · Seminars in Avian and Exotic Pet Medicine · doi:10.1053/saep.2002.28236 · Cited by 144
Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season
Allison, M. A., Daley, M. F., Crane, L. A., et al. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.06.036 · Cited by 121
Ansaldi, F., Zancolli, M., Durando, P., Montomoli, E., Sticchi, L., Del Giudice, G., & Icardi, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.04.030 · Cited by 96
Heinonen, S., Silvennoinen, H., Lehtinen, P., Vainionpää, R., Ziegler, T. T., & Heikkinen, T. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70255-3 · Cited by 96
Responses to 2009 H1N1 Vaccine in Children 3 to 17 Years of Age
Arguedas, A. G., Soley, C., & LINDERT, K. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0909988 · Cited by 62
Antibody Responses to Influenza B Viruses in Immunologically Unprimed Children
Levandowski, R. A., Regnery, H. L., Staton, E., Burgess, B. G., Williams, M. S., & Groothuis, J. R. (1991) · PEDIATRICS · doi:10.1542/peds.88.5.1031 · Cited by 60
Heikkinen, T., Booy, R., Campins, M., Finn, A. H. R., Olcén, P., Peltola, H., Rodrigo, C., Schmitt, H., Schumacher, F., Teo, S. S. S., et al. (2005) · European Journal of Pediatrics · doi:10.1007/s00431-005-0040-9 · Cited by 58
Self-citationAmbrose, C. S., Wu, X., & Belshe, R. B. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181e2872f · Cited by 55
Banzhoff, A., Haertel, S., & Praus, M. (2011) · Human Vaccines · doi:10.4161/hv.7.5.14821 · Cited by 50
BLACK, S. B., Cioppa, G. D., Malfroot, A., Nacci, P., Nicolay, U., Pellegrini, M., Sokal, E. M., & Vertruyen, A. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.075 · Cited by 41
Cited by
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6703a1 · Cited by 1,632
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Del Giudice, G., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 610
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Olsen, S. J., Karron, R. A., Jernigan, D. B., & Bresee, J. S. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6505a1 · Cited by 593
The mechanism of action of MF59 – An innately attractive adjuvant formulation
O’Hagan, D. T., Ott, G. S., De Gregorio, E., & Seubert, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.09.061 · Cited by 488
Traditional and New Influenza Vaccines
Wong, S.-S., & Webby, R. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00097-12 · Cited by 372
Metadata
- Authors
- Vesikari, T., Knuf, M., Wutzler, P., Karvonen, A., Kieninger-Baum, D., Schmitt, H.-J., Baehner, F., Borkowski, A., Tsai, T. F., & Clemens, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-10-13
- Volume
- 365
- Issue
- 15
- Pages
- 1406-1416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2028587022
- Cited by
- 317
- References
- 34
- FWCI
- 28.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.